Jay T. Backstrom's most recent trade in Agios Pharmaceuticals Inc was a trade of 23,393 Stock options (right to buy) done . Disclosure was reported to the exchange on July 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | Jay T. Backstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2025 | 23,393 | 23,393 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Jay T. Backstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2025 | 4,341 | 4,341 | - | - | Restricted stock units | |
| Scholar Rock Holding Corp | Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 151,430 | 151,430 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 113,570 | 425,561 (1%) | 0% | 0 | Common Stock | |
| Scholar Rock Holding Corp | Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 36.83 per share. | 18 Feb 2025 | 18,372 | 311,991 (1%) | 0% | 36.8 | 676,622 | Common Stock |
| LAVA Therapeutics NV | Jay T. Backstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 33,390 | 33,390 | - | - | Common Shares (Right to Buy) | |
| Scholar Rock Holding Corp | Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 16 Jan 2025 | 22,308 | 330,363 (1%) | 0% | 44.2 | 985,951 | Common Stock |
| Scholar Rock Holding Corp | Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | 16 Feb 2024 | 11,614 | 352,671 (1%) | 0% | 15.7 | 182,842 | Common Stock | |
| Scholar Rock Holding Corp | Jay T. Backstrom | Director, CHIEF EXECUTIVE OFFICER | 12 Feb 2024 | 285,715 | 285,715 | - | - | Stock Option (Right to Buy) | ||
| Scholar Rock Holding Corp | Jay Backstrom T. | Director, CHIEF EXECUTIVE OFFICER | 12 Feb 2024 | 214,285 | 364,285 (1%) | 0% | 0 | Common Stock | ||
| Scholar Rock Holding Corp | Jay T. Backstrom | CHIEF EXECUTIVE OFFICER | 13 Feb 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | ||
| Scholar Rock Holding Corp | Jay T. Backstrom | CHIEF EXECUTIVE OFFICER | 13 Feb 2023 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | ||
| Disc Medicine Inc | Jay T. Backstrom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2022 | 7,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | Jay T. Backstrom | CEO-Elect | 20 Sep 2022 | 1,000,000 | 1,000,000 | - | - | Stock Option (right to buy) |